Jubilant Pharmova's Vision 2030: Charting a Course for Double-Digit Growth and Strategic Expansion

Jubilant Pharmova, a diversified pharmaceutical company, has laid out an ambitious Vision 2030, aiming to significantly scale its operations and enhance profitability across its key segments. The company's latest investor presentation for Q3 and 9M FY26 reveals a strong focus on specialty products and services, with a clear roadmap for expansion, innovation, and market leadership. For the 9M FY26 period, the company reported a total revenue of Rs. 5,990 Crore, demonstrating solid performance driven by its core businesses.

The Radiopharma segment continues to be a cornerstone of Jubilant Pharmova's growth, contributing approximately 45.08% of the 9M FY26 revenue with Rs. 2,700 Crore. This segment benefits from a robust US market, which is expanding at a 20% CAGR, fueled by advancements in PET imaging and therapeutic products. The company is a leading manufacturer in North America, boasting the second-largest radiopharmacy network in the US. Similarly, the CDMO Sterile Injectables segment, accounting for 20.37% of revenue (Rs. 1,220 Crore), is experiencing a widening demand-supply gap, positioning Jubilant Pharmova favorably as innovator pharma companies seek onshore manufacturing solutions. The CRDMO segment, with Rs. 899 Crore (15.01% of revenue), is also poised for growth, leveraging India's unique position to benefit from 'Friendshoring' and specialized CDMO services. While Allergy Immunotherapy (Rs. 568 Crore, 9.48%) and Generics (Rs. 559 Crore, 9.33%) also contribute, the focus remains on high-margin specialty areas.

Strategic Pillars for Vision 2030

Jubilant Pharmova's Vision 2030 is built on several strategic pillars designed to double revenues, expand margins, and achieve a zero-net-debt status. The company aims for a total revenue of Rs. 13,500 Crore by FY30, with an EBITDA margin target of 23-25%. This ambitious growth is underpinned by significant investments and strategic initiatives across its segments.

In Radiopharma, the company plans to more than double its FY24 revenue by FY30, targeting EBITDA margins exceeding 50%. A key initiative is the expansion of its PET radiopharmacy network from 3 to 9 sites, expected to be fully operational by FY28. This USD 50 million investment is projected to yield an asset turnover of 1.0x and a RoCE of over 20%. Furthermore, Jubilant Pharmova is set to launch 9 new PET and SPECT imaging products between FY27 and FY29, aiming to increase its total addressable market by USD 550 million and achieve peak annual sales of USD 120 million. The company is also progressing with MIBG, a therapeutic product for pediatric cancer, with an NDA filing anticipated in H2 FY27.

The CDMO Sterile Injectables segment is set for substantial capacity expansion. The Line 3 at Spokane is transitioning to commercial batch production in FY27, with a peak revenue potential of USD 80-90 million. Additionally, a new Isolator Fill & Finish Line (Line 5) is under construction at Montreal, involving a Capex of USD 114 million, with technology transfer revenues expected to commence in FY29. These expansions are critical to capitalize on the increasing demand and high entry barriers in the sterile injectables market, with a Vision 2030 target of more than doubling FY24 revenues and achieving EBITDA margins over 25%.

Innovation and Market Positioning

Jubilant Pharmova is also strengthening its CRDMO and API businesses. The Drug Discovery Services (DDS) segment is undergoing a significant capacity expansion, with FTEs projected to grow from 1,000 in FY25 to 4,000 in FY30, backed by a USD 150 million Capex and an expected RoCE of over 20%. This expansion, coupled with a strategic partnership with Pierre Fabre, adds biologics capabilities, expanding the total addressable market by USD 1.4 billion in mAbs and ADCs. The API business is focusing on custom manufacturing and CDMO services, leveraging a